Virogin Biotech Announces Abstract Publication at the American Society of Clinical Oncology Annual Meeting
VANCOUVER, BC – Virogin Biotech today announced the acceptance of an abstract detailing initial results from its first in human trial of VG161 – the company’s lead product candidate. The abstract will be available during the virtual American Society of Clinical Oncology (ASCO) Annual Meeting 2021, taking place from June 4-8, 2021.
Details on the abstract are below. The abstract is available on the ASCO Annual Meeting website.
Title: Initial results from a first in human trial incorporating accelerated dose titration of a novel immune stimulating oncolytic virus – VG161
Presentation Type: Abstract
Session Title: Developmental Therapeutics – Immunotherapy
Abstract Number: e14574
VG161 is an attenuated herpes simplex virus type 1 (HSV-1), built on Virogin’s Synerlytic™ Platform, which expresses a unique combination of cytokines that act synergistically to boost the innate and adaptive immune responses in the tumor microenvironment. VG161 has a deletion of the ICP34.5 gene to prevent neurovirulence.
About Virogin Biotech
Virogin Biotech is a clinical stage oncolytic virus company that is developing next-generation oncolytic virotherapies to enhance the systemic antitumor immunity. Led by a team with over 25 years of experience in fundamental research, translational and clinical development of immunotherapy & oncolytic virotherapy, Virogin is determined to be a global, best-in-class oncolytic virus company that creates impactful therapies for patients of the highest medical need.